Lifevantage Corp (LFVN) — SEC Filings
Lifevantage Corp (LFVN) — 20 SEC filings. Latest: 8-K (Dec 9, 2025). Includes 7 8-K, 6 10-Q, 2 DEF 14A.
View Lifevantage Corp on SEC EDGAR
Overview
Lifevantage Corp (LFVN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 9, 2025: LifeVantage Corp. announced on December 3, 2025, the departure of Director W. Kirk Beecroft and the appointment of new Director Dr. Robert Sinnott. The company also reported on compensatory arrangements for its named executive officers, though specific details of these arrangements were not provided
Sentiment Summary
Across 20 filings, the sentiment breakdown is: 17 neutral, 3 mixed. The dominant filing sentiment for Lifevantage Corp is neutral.
Filing Type Overview
Lifevantage Corp (LFVN) has filed 7 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13D/A, 1 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (20)
Risk Profile
Risk Assessment: Of LFVN's 18 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $47.561M |
| Net Income | $2.155M |
| EPS | $0.17 |
| Debt-to-Equity | 0.86 |
| Cash Position | $13.091M |
| Operating Margin | 4.77% |
| Total Assets | $61.579M |
| Total Debt | $28.422M |
Key Executives
- W. Kirk Beecroft
- Dr. Robert Sinnott
- Steven R. Fife
- Michael J. Stewart
- Dr. Steven G. Stevanov
- Bradley L. Radoff
- Ryan Nebel
Industry Context
LifeVantage operates within the highly competitive global health and wellness market, which is characterized by a growing consumer focus on preventative health and natural products. The direct selling channel, while effective for reaching niche markets and building communities, faces increasing regulatory scrutiny and requires robust distributor engagement strategies. Key trends include the rise of personalized nutrition and the increasing demand for science-backed supplements.
Top Tags
corporate-governance (3) · filing-update (3) · 10-Q (3) · shareholder-vote (2) · Nutrigenomics (2) · Direct Selling (2) · financials (2) · Lifevantage Corp (2) · amendment (2) · director-change (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $2.155M | Increased from $1.826M in Q1 2024 |
| Revenue, net | $47.561M | Slight increase from $47.214M in Q1 2024 |
| Cash and Cash Equivalents | $13.091M | Decreased from $20.201M at June 30, 2025 |
| Decrease in Cash and Cash Equivalents | $7.110M | Significant cash outflow during the quarter |
| Net Cash Used in Operating Activities | $2.305M | Primary driver of cash decrease |
| Net Cash Used in Financing Activities | $4.297M | Contributed to cash decrease |
| Operating Income | $2.268M | Decreased from $2.570M in Q1 2024 |
| Shares Outstanding | 12,701,187 | As of November 3, 2025 |
| Total Assets | $61.579M | Decreased from $71.958M at June 30, 2025 |
| Total Liabilities | $28.422M | Decreased from $37.317M at June 30, 2025 |
| Annual Meeting Date | November 6, 2025 | Date of the Fiscal Year 2026 Annual Meeting of Stockholders |
| Record Date | September 15, 2025 | Date for determining stockholders entitled to vote at the Annual Meeting |
| Number of Directors | 7 | Number of directors to be elected for a one-year term |
| Sodali & Co. Fee | $10,000 | Approximate fee paid to Sodali & Co. for proxy solicitation services |
| Fiscal Year End | June 30, 2026 | End date for the fiscal year for which Deloitte is appointed auditor |
Forward-Looking Statements
- {"claim":"Renaissance Technologies LLC will maintain a passive investment strategy in Lifevantage Corporation.","entity":"Renaissance Technologies LLC","targetDate":"Next 12 months","confidence":"high"}
- {"claim":"Lifevantage Corporation's stock price will not experience significant volatility directly due to this specific filing.","entity":"Lifevantage Corporation","targetDate":"Next 30 days","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Lifevantage Corp (LFVN)?
Lifevantage Corp has 20 recent SEC filings from Jan 2024 to Dec 2025, including 7 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LFVN filings?
Across 20 filings, the sentiment breakdown is: 17 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Lifevantage Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lifevantage Corp (LFVN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lifevantage Corp?
Key financial highlights from Lifevantage Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LFVN?
The investment thesis for LFVN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lifevantage Corp?
Key executives identified across Lifevantage Corp's filings include W. Kirk Beecroft, Dr. Robert Sinnott, Steven R. Fife, Michael J. Stewart, Dr. Steven G. Stevanov and 2 others.
What are the main risk factors for Lifevantage Corp stock?
Of LFVN's 18 assessed filings, 1 were flagged high-risk, 8 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Lifevantage Corp?
Recent forward-looking statements from Lifevantage Corp include guidance on {"claim":"Renaissance Technologies LLC will maintain a passive investment strategy in Lifevantage Corporation.","entity" and 1 other predictions.